Mural Oncology plc (NASDAQ:MURA) shares traded 0.41% higher at $2.42 on Wall Street last session.
MURA stock price is now -20.79% away from the 50-day moving average and -27.65% away from the 200-day moving average. The market capitalization of the company currently stands at $41.69M.
With the price target maintained at $18, Raymond James recently Downgraded its rating from Strong Buy to Outperform for Mural Oncology plc (NASDAQ: MURA). , while ‘Rodman & Renshaw’ rates the stock as ‘Buy’
In other news, Loew Caroline, Officer bought 4,313 shares of the company’s stock on Mar 04 ’25. The stock was bought for $14,491 at an average price of $3.36. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 05 ’25, Keson-Brookes Maiken sold 1,469 shares of the business’s stock. A total of $5,068 was realized by selling the stock at an average price of $3.45. This leaves the insider owning 73,564 shares of the company worth $0.18 million. A total of 10.97% of the company’s stock is owned by insiders.
During the past 12 months, Mural Oncology plc has had a low of $0.95 and a high of $4.74. As of last week, the company has a debt-to-equity ratio of 0.06, a current ratio of 5.83, and a quick ratio of 5.83. The fifty day moving average price for MURA is $3.0551 and a two-hundred day moving average price translates $3.344875 for the stock.
The latest earnings results from Mural Oncology plc (NASDAQ: MURA) was released for 2024-12-31. The company reported revenue of $35.85 million for the quarter, compared to $58.51 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -38.72 percent.
